Search results for "Discovery and development of direct thrombin inhibitors"

showing 4 items of 4 documents

Interaction of inflammation, thrombosis, aspirin and enoxaparin in CNS experimental antiphospholipid syndrome

2008

Experimental antiphospholipid syndrome (eAPS) induced by immunization with beta(2)-glycoprotein I (beta(2)-GPI) causes behavioral hyperactivity. We assessed the role of thrombotic and inflammatory perivascular factors and standard APS therapies for CNS manifestations. Groups of mice (n=10 per group) were immunized once with beta(2)-GPI (eAPS) or adjuvant (controls) and treated daily from 1 month after immunization with either sham injections, aspirin (1.2 mg/kg) or enoxaparin (1 mg/kg) for 3 months. Serum antiphospholipid antibodies (aPL) and brain levels of tissue necrosis factor-alpha (TNF-alpha) and prostaglandin E (PGE) were then measured by ELISA and thrombin inhibitors by immunoblot. …

Central Nervous Systemmedicine.medical_treatmentEnzyme-Linked Immunosorbent AssayInflammationPharmacologylcsh:RC321-571AnticoagulationMiceFibrinolytic AgentsAntiphospholipid syndromeAnimalsMedicineBeta 2-Glycoprotein IAlprostadilEnoxaparinlcsh:Neurosciences. Biological psychiatry. NeuropsychiatryPhospholipidsInflammationBehaviorAnalysis of VarianceMice Inbred BALB CAspirinAspirinBehavior AnimalTumor Necrosis Factor-alphabusiness.industryThrombosisAntiphospholipid Syndromemedicine.diseaseThrombosisAnimal modelsDisease Models AnimalNeurologybeta 2-Glycoprotein IImmunologyExploratory BehaviorFemaleTumor necrosis factor alphamedicine.symptombusinessDiscovery and development of direct thrombin inhibitorsProstaglandin Emedicine.drugNeurobiology of Disease
researchProduct

Prothrombinase-Induced Clotting Time Assay for Determination of the Anticoagulant Effects of Unfractionated and Low-Molecular-Weight Heparins, Fondap…

2008

The prothrombinase-induced clotting time assay (PiCT, Pentapharm, Basel, Switzerland) is a clotting assay sensitive to factor Xa and factor IIa inhibitors. It is based on the addition of factor Xa and snake venom RVV-V (Russell viper venom factor V activator) specifically activating factor V and phospholipids to platelet-poor plasma. Following an incubation time, the mixture is recalcified and the clotting time is determined. An almost linear dose-response and high sensitivity of the assay for unfractionated heparin (UFH), low-molecular-weight heparins (LMWHs), r-hirudin, and argatroban was found. Fondaparinux showed a nonlinear dose-response. By using ex vivo samples, the following Pearson…

HeparinChemistryHirudinGeneral MedicineHeparin Low-Molecular-WeightPharmacologyFondaparinuxSensitivity and SpecificityFondaparinux SodiumArgatrobanThromboplastinThrombinFibrinolytic AgentsFondaparinuxBiochemistryClotting timePolysaccharidesProthrombinasemedicineHumansBlood Coagulation Testsmedicine.drugDiscovery and development of direct thrombin inhibitorsAmerican Journal of Clinical Pathology
researchProduct

THE ROLE OF THROMBIN IN CENTRAL NERVOUS SYSTEM ACTIVITY AND STROKE

2018

Background. Thrombin is a key factor of hemostasis, mediating the conversion of fibrinogen into fibrin. Along with prothrombin, of which thrombin is the active derivative, it has been found locally expressed in the central nervous system. This article aims to describe the role of thrombin in the normal functioning of the central nervous system and stroke.Methods. In this mini-review, the specialized databases Medscape, PubMed, and Web of Science, from the years 2003-2018, were used to find relevant documents by using MeSH terms: ”thrombin” and ”stroke”.Results. Prothrombin and thrombin influence neural development, protection and regeneration, thrombin being a relatively strong regulating f…

biologybusiness.industryCerebral infarctionReviewGeneral MedicinePharmacologycentral nervous systemFibrinogenmedicine.diseasethrombinstrokeFibrinDabigatranThrombinNeurologyHemostasisbiology.proteinmedicinebusinessStrokecirculatory and respiratory physiologyDiscovery and development of direct thrombin inhibitorsmedicine.drugMedicine and Pharmacy Reports
researchProduct

Antivitamin K Drugs in Stroke Prevention

2014

Among the different subtypes of ischaemic strokes, almost 20 % are of cardiac origin. Different are the causes of cardioembolic stroke, but the most common is the atrial fibrillation, a supraventricular arrhythmia. Appropriate use of antiplatelet drugs and anticoagulants after transient ischaemic attack (TIA) or ischaemic stroke depends on whether the underlying cause is cardioembolic or of presumed arterial origin. Adequate antiplatelet therapy is recommended for secondary prevention after cerebral ischaemia of presumed arterial origin, whether for patients with TIA and ischaemic stroke of cardiac origin, mainly due to atrial fibrillation. Vitamin K antagonists (VKAs) are highly effective …

medicine.medical_specialtyVitamin KSettore MED/09 - Medicina InternaAppropriate useInternal medicinemedicineAnimalsHumanscardiovascular diseasesRandomized Controlled Trials as TopicPharmacologySupraventricular arrhythmiabusiness.industryPatient choiceStandard treatmentAnticoagulantsVKAs Stroke preventionAtrial fibrillationmedicine.diseaseStrokeIschemic Attack TransientStroke preventionCardiologyCerebral ischaemiaCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation InhibitorsDiscovery and development of direct thrombin inhibitorsCurrent Vascular Pharmacology
researchProduct